Prognosis
Moderna Seeks U.S. Authorization for Covid Booster Shot
- In trial, third dose raised antibodies versus delta by 40-fold
- FDA advisers plan to review Pfizer booster data on Sept. 17
This article is for subscribers only.
Moderna Inc. said that it had filed initial data with the U.S. Food and Drug Administration for clearance of a third-dose booster of its Covid-19 vaccine, adding fuel to a debate over the need for additional shots.
In a statement on Wednesday, the company said the booster shot, using a reduced dose of 50 micrograms that is half the dose used in the existing vaccine, raised antibody levels against the delta variant by more than 40-fold in a clinical trial.